|
V.V. Fomin, L.V. Kozlovskaya, Yu.S. Milovanov, L.Yu. Milovanova
Cardio-renal anemia syndrome: correction with iron sucrose
|
№4 / 2011
|
|
V.Yu. Shilo, A.Yu. Denisov
Treatment of anemia in chronic kidney disease: the present, the past and the future
|
№3 / 2011
|
|
P.A. Vorobyev, L.Yu. Bezmenitsina
Epidemiology and quality of life in patients with chronic renal failire and anemia, receiving programm hemodyalisis. Part 2. Quality of life and costs of erythropoietin treatment
|
№2 / 2011
|
|
Yu.S. Milovanov, L.Yu. Milovanov, L.V. Kozlovskaya
Use of trihydric iron preparations in treatment of anemia in patients with pre-dialysis renal failure
|
№2 / 2011
|
|
E.V. Shutov, S.V. Lashutin, I.G. Kolomiitseva, E.V. Shuvalov
Treatment of anemia with methoxypolyethyleneglycol – epoetin beta in patients on haemodyalisis
|
№2 / 2011
|
|
P.A. Vorobev, L.J. Bezmelnitsyna
Epidemiology and quality of life in patients with chronic renal failire and anemia, receiving programm hemodyalisis. Part 1. Epidemiology and use of erythropoietin medications
|
№1 / 2011
|
|
J.S. Milovanov, L.J. Milovanova, L.V. Kozlovskaya
Anaemia in chronic kidney disease: pathogenesis, prognostic sighnificance, treatment
|
№6 / 2010
|
|
M.A. Shestakova, S.A. Martynov
Anaemia correction in diabetic nephropathy: target haemoglobin values and cardiovascular complications
|
№5 / 2010
|
|
L.V. Kozlovskaya, Yu.S. Milovanov, L.Yu. Milovanova, I.A. Dobrosmislov
Difficulties in renal anemia treatment. Role of prolonged erythropoietin receptor activator
|
№2 / 2010
|
|
R.R. Kaliev, A.B. Budaichieva, I.T. Murkamilov
Renal anemia influence on kidney function and survival of patients with chronic glomerulonephritis
|
№1 / 2010
|
|
M.Yu. Shvetsov, MD, PhD; A.A. Ivanov, MD, PhD, Prof; O.P. Popova, MD; A.V. Kuznetsova, MD, PhD; A.S. Rameeva
Renal expression of hypoxia-induced factor-1, anemia and nephrosclerosis severity in chronic glomerulonephritis.
|
№2 / 2009
|
Русский
